You can buy or sell JAZZ and other stocks, options, ETFs, and crypto commission-free!
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. Read More The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Dublin, Ireland.
52 Week High
52 Week Low
Simply Wall St18h
Is Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) 16% ROE Better Than Average?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important.
FDA approves Jazz Pharma's Sunosi
The FDA has approved Jazz Pharmaceuticals' (NASDAQ:JAZZ) Sunosi (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). Sunosi is the first dual-acting dopamine and norepinephrine reuptake inhibitor approved. It is expected to be available in the U.S. following the final scheduling decision by the U.S. Drug Enforcement Administration, which is typically within 90 days of FDA approval....
Expected May 7, After Hours